Connect with us

Artificial Intelligence

Predictive Oncology Completes Acquisition of Quantitative Medicine

GlobeNewswire

Published

on

MINNEAPOLIS, July 07, 2020 (GLOBE NEWSWIRE) — Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced it has completed its acquisition of Quantitative Medicine LLC (“QM”), a biomedical analytics and computational biology company, in an all-stock transaction valued at approximately $1.8 million.
QM, which was cofounded by Drs. Robert Murphy and Joshua Kangas, both of Carnegie Mellon University’s Computational Biology Department, developed its novel, computational drug-discovery platform CoRETM, an innovative machine learning platform that predicts the main effects of drugs on target molecules that mediate disease, which is expected to dramatically reduce the time, cost and financial risk of discovering new therapeutic drugs.“This acquisition will enable us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing,” commented Dr. Carl Schwartz, Predictive Oncology’s CEO. “Integrating QM’s proven machine learning platform, CoRE, with our proprietary database of drug response and genomics profiles is expected to revolutionize the role of our AI-driven predictive models in the discovery and development of new anti-cancers. We will be able to more quickly understand how specific types of tumors react to cancer drug therapies. This will allow our customers to accelerate the development and commercialization of personalized patient treatments that dramatically improve patient outcomes. We intend to offer this new capability to our pharmaceutical company customers in revenue generating projects this year.”Dr. Schwartz added, “CoRE is a predictive model-building platform for drug screening and optimization campaigns that uses hybrid machine learning approaches to build predictive models rapidly and drive wet lab experimentation. Unlike the approach of many AI companies working purely “in silico,” our approach will unite the CoRE approach with our PDx tumor profiling platform and tumor data database, allowing for a one-of-a-kind, end-to-end ‘discovery machine’ that can rapidly generate potential therapeutic candidates in a cost-effective manner. Therapeutic candidates developed by this iterative AI and experiment cycle can be fast-tracked, since there will already be demonstrated activity in preclinical laboratory tests rather than just a computer model.”“Furthermore, the CoRE platform is disease neutral and coupled with Helomics’ CLIA laboratory offers the exciting possibility of providing a wide range of new revenue generating projects with Pharmaceutical companies, not just in cancer, but in inflammatory and metabolic disease as well as the search for new antibiotics, anti-viral and vaccines,” added Dr Mark Collins, Chief Technology Officer at Helomics.Under the terms of the purchase agreement, Predictive Oncology issued 954,719 shares of its common stock at a valuation of $1.833 per share. Additional details regarding the transaction can be found on the company’s report filed on Form 8-K with the Securities and Exchange Commission on July 7, 2020.About Predictive Oncology Inc.Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies AI to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The Company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.Forward-Looking StatementsPortions of the narrative set for this document that are not statements of historical or current facts are forward-looking statements, in particular, the commercial outlook provided above. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors.These factors include, in addition to those mentioned elsewhere herein:We may not be able to continue operating without additional financing;Current negative operating cash flows;The terms of any further financing, which may be highly dilutive and may include onerous terms;Risks related to the 2019 merger with Helomics including; 1) significant goodwill could result in further impairment; 2) possible failure to realize anticipated benefits of the merger; 3) costs associated with the merger may be higher than expected; 4) the merger may result in the disruption of our existing businesses; and 5) distraction of management and diversion of resources;Risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns;Risks related to the transaction with Quantitative Medicine including: 1) possible failure to realize anticipated benefits of the transaction; 2) costs associated with the acquisition may be higher than expected; 3) the transaction may result in the disruption of our existing businesses; and 4) distraction of management and diversion of resources;Risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property;The impact of competition;Acquisition and maintenance of any necessary regulatory clearances applicable to applications of our technology;Inability to attract or retain qualified senior management personnel, including sales and marketing personnel;Risk that we never become profitable if our product is not accepted by potential customers;Possible impact of government regulation and scrutiny;Unexpected costs and operating deficits, and lower than expected sales and revenues, if any;Adverse results of any legal proceedings;The volatility of our operating results and financial condition;Management of growth;Material and adverse effects of the COVD-19 pandemic, including impact on a significant supplier; a reduction in on-site staff at several of our facilities, resulting in delayed production and less efficiency; impact on sales efforts; impact on accounts receivable and terms demanded by suppliers; and possible impact on financing transactions; and,Other specific risks that may be  detailed from time to time in the Company’s reports filed with the SEC, which are available for review at www.sec.gov..Investor Relations Contact:Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Flavor Enhancers Market To Reach USD 11.5 Billion By 2027 | Reports and Data

GlobeNewswire

Published

on

New York, Aug. 12, 2020 (GLOBE NEWSWIRE) — According to the analysis of Reports and Data, the Global Flavor Enhancers Market was valued at USD 6.6 billion in 2019 and is expected to reach USD 11.5 billion by the year 2027, growing at a CAGR of around 6.5%. According to the Food and Drug Administration (FDA), flavor enhancers are the substances that have no pronounced flavor or taste of their own but which bring out and improve the flavors in the foods to which they are added. The term flavor potentiator has also been used with the same meaning. The most commonly used substances in this category are monosodium L-glutamate (MSG), disodium 5′-inosinate (IMP), and disodium 5′-guanylate (GMP).

The growth of the segment is driven by the expansion of the global beverage industry, an increase in demand for convenience food, changing consumer lifestyle, and an increase in the number of sensory-oriented consumers worldwide. The global flavor enhancers market is expected to witness an upsurge owing to the introduction of new food products with natural ingredients and coloring pigments. Furthermore, technological advancements, growing demand for clean label products, and stringent regulations on synthetic enhancers are influencing manufacturers to incorporate more natural flavors in their offerings. Increasing the use of natural flavor enhancers by the food processing industry is a key factor driving the flavor enhancers market’s growth.

However, factors such as mounting raw material prices and high entry barriers and price pressure on manufacturers due to consolidation affect the industry’s growth. Major trends prevailing in the market are consolidation in the industry, demand for substitutes for artificial flavor enhancers, the emergence of biotech flavor enhancers, and sensory trend.

The global flavor enhancers market is segregated based on type glutamates, acidulants, hydrolyzed vegetable protein, yeast extracts, and others (sweetness enhancers and nucleotides). Based on form, the global flavor enhancers market is segmented in Powder and Liquid & Semi-Liquid. Based on source, the market is segmented into natural and synthetic. Based on application, the market is bifurcated into processed & convenience foods, meat & fish products, beverages, and others (confectionery products, bakery, dairy, and condiments).

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/3408

Further key findings from the report suggest

  • By type, the glutamates segment was valued at USD 1.36 billion in 2019. Asia is the largest producer of glutamates, including MSG, accounting for approximately 93% of the global MSG production capacity. Greater demand, an economic and abundant workforce, and its use in processed foods are the prime reasons behind its significant production in Asia. Indonesia, China, Taiwan, Thailand, and Malaysia are the major glutamate manufacturers. China is one of the top manufacturers (66%), the consumer (51%), and exporter (49%) of MSG worldwide. Indonesia is the second-largest (15%) exporter of glutamates. The FDA reported that the Middle East and Africa consumed 4%, Europe 3%, North America 2%, and central and South America 2% MSG.
  • Among the application segments, processed & convenience foods occupied a significant share of about 38.3% in the flavor enhancers market. Flavor enhancers like lactic acid find extensive application in the processed & convenience food industry as it benefits from regulating microflora in the food and acting as preservatives. It is formed by the natural fermentation process in food products such as pickled vegetables, cheese, and soy sauce.
  • Among the source segments, the natural segment leis growing at a rapid CAGR of 6.8%. The snowballing health awareness among the population and the rising demand for organic foods and upsurge in the buying power of the population fosters the market growth. Offering unique and tastier flavor enhancers would principally boost the demand in the global natural food flavor enhancers market.
  • By form, the liquid segment is projected to grow at the fastest CAGR 6.5% during the analysis period. Factors such as minimized ingredient loss, high consistency and uniformity, specification-oriented superior quality production, and excellent microbiological safety drive the market.
  • North America occupied a share market share of about 33.5% in 2019 in the flavor enhancers market. Established key market players and continued investments from manufacturers are likely to drive market growth in North America during the forecast period.
  • The key players in the market include Tate & Lyle PLC, Cargill, Corbion N.V., Associated British Foods plc, Sensient Technologies, ADM, Novozymes A/S, E.I. Dupont, Angel Yeast Co., Ltd, Innova Flavors, Savoury Systems International, Inc., Senomyx, Inc and Ajinomoto Co, Inc.
  • In November 2019, Archer Daniels Midland Co. acquired Florida Chemical Company., which is specialized in citrus-based fragrances and flavors. Florida Chemical Co., a subsidiary of Flotek Industries based in Winter Haven. It offers citrus flavor materials and essential oils as well as flavor enhancers for grapefruit and other citruses.

BUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/3408

For the purpose of this report, Reports and Data has segmented the Global Flavor Enhancers Market on the basis of type, application, source, form, and region:

Type Outlook (Revenue, USD Billion; 2017-2027)

  • Glutamates
  • Acidulants
  • Hydrolyzed vegetable protein
  • yeast extracts
  • Others (sweetness enhancers and nucleotides)

Application Outlook (Revenue, USD Billion; 2017-2027)

  • Processed & convenience foods  
  • Meat & fish products
  • Beverages
  • Bakery
  • Confectionery products
  • Dairy
  • others

Source Outlook (Revenue, USD Billion; 2017-2027)

  • Natural
  • Synthetic

Form Outlook (Revenue, USD Billion; 2017-2027)

  • Powder
  • Liquid & semi-liquid

To identify the key trends in the industry, click on the link below:   https://www.reportsanddata.com/report-detail/flavor-enhancers-market

Regional Outlook (Revenue, USD Million; 2017-2027)

  • North America
  • U.S
  • Canada
  • Europe
  • U.K
  • France
  • Italy
  • Spain
  • Germany
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Rest of LATAM
  • Middle East & Africa

Take a Look at our Related Reports:

Instant Coffee Market: https://www.reportsanddata.com/report-detail/global-instant-coffee-market-by-manufacturers-countries-type-and-application-forecast-to-2022

Isoflavones Market: https://www.reportsanddata.com/report-detail/isoflavones-market

Krill Oil Market: https://www.reportsanddata.com/report-detail/krill-oil-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com

Continue Reading

Artificial Intelligence

Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease

GlobeNewswire

Published

on

— Companies to jointly validate novel drug targets —
— Scipher eligible for upfront, opt-in and milestone payments —
— Galapagos to progress selected targets into drug discovery —

Mechelen, Belgium and Boston, USA; 12 August 2020 – Galapagos NV (Euronext & Nasdaq: GLPG) and Scipher Medicine (Scipher), a Boston based privately held precision medicine company focused on autoimmune diseases, today announce a collaboration to advance novel drug targets identified by Scipher for the treatment of inflammatory bowel disease (IBD).
   
Scipher combines its proprietary Network Medicine Platform with molecular patient data and AI-based methods to identify novel targets and pathways in autoimmune diseases, including IBD.

Scipher and Galapagos will jointly validate a suite of novel IBD targets discovered by Scipher after which Galapagos has the exclusive option to progress up to five targets into further drug discovery and development. Under the terms of the agreement, Scipher is eligible to receive upfront, opt-in and milestone payments and Galapagos will retain the rights for the discovery, development and commercialization of therapeutics for the selected target(s).

“Our breakthrough approach combines extensive patient-level molecular data with AI methods to discover novel targets with the potential to treat specific groups of patients, including those not responding to therapies currently available,” said Alif Saleh, Chief Executive Officer of Scipher Medicine. “This partnership with Galapagos is a recognition of our innovative approach to discover and validate novel targets that could offer a solution for IBD patients.”

“The collaboration with Scipher is aligned with our strategy to discover and develop novel modes of action medicines with the potential to disrupt current treatment paradigms to address high unmet needs in inflammatory diseases,” said Piet Wigerinck, Chief Scientific Officer of Galapagos. “We believe that our drug discovery and development expertise alongside Scipher’s platform will support us in the discovery of exciting new drug candidates.”

About Scipher Medicine
Scipher Medicine, a precision immunology company, holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data. Leveraging our proprietary Network Medicine platform and artificial intelligence, we commercialize blood tests identifying a patient’s unique molecular disease signature and match such signature to most effective therapy ensuring patients receive optimal treatment from day one. The unprecedented amount of patient molecular data generated from our tests further drives development of novel and more effective therapeutics. We partner with payers, providers and pharma along the health care value chain to bring precision medicine to autoimmune diseases.

Scipher Medicine is backed by Khosla Ventures, Northpond Ventures and UnitedHealth Group.
Visit www.sciphermedicine.com and follow Scipher on Twitter, Facebook and LinkedIn.

About Galapagos
Galapagos NV discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Galapagos Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the inherent uncertainties associated with target discovery and validation and drug discovery and development activities (including that data from the ongoing discovery activities may not support the validation of any novel IBD targets or the development of any IBD drug candidates with novel modes of action), expectations regarding the collaboration with Scipher, that Galapagos may decide not to exercise any option granted to it under the agreement with Scipher, and that Galapagos’ expectations regarding the further development of any potential future in-licensed program, including its potential to address a large unmet need in inflammatory diseases, may be incorrect, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended December 31, 2019 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.

###

Galapagos Contacts:
Investors:
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15
ir@glpg.com

Media:
Carmen Vroonen
Head of Internal & External Communications & Public Affairs
+32 473 824 874

Anna Gibbins
Senior Director Communications – Therapeutic Areas
+44 7717 801900
communications@glpg.com

Media contacts Scipher Medicine:
Cassidy McClain
Cassidy@canalecomm.com
+1 619.849.6009

Brian McEvilly
brian.mcevilly@sciphermedicine.com
+1 858.736.5517

Attachment

Continue Reading

Artificial Intelligence

OMNIQ Corp. to Host Second Quarter Earnings Call on Friday, August 14, 2020 at 11:00 AM ET

GlobeNewswire

Published

on

SALT LAKE CITY, Aug. 12, 2020 (GLOBE NEWSWIRE) — OMNIQ Corp. (OTCQB: OMQS) (“OMNIQ” or “the Company”), a provider of Supply Chain and Artificial Intelligence (AI)-based solutions, will host a conference call and webcast on Friday, August 14, 2020 at 11:00 a.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2020.

To access the live webcast, please click on this webcast link to register, or go to the Company’s website at www.questsolution.com, and click on the About tab, then Investors. 

To participate in the call by phone, dial (877) 407-9210 approximately five minutes prior to the scheduled start time. International callers please dial (201) 689-8049.

A replay of the teleconference will be available until September 13, 2020 and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use conference ID: 36627.

About OMNIQ Corp.
OMNIQ Corp. (OTCQB: OMQS) provides computerized and machine vision image processing solutions that use patented and proprietary AI technology to deliver data collection, real time surveillance and monitoring for supply chain management, homeland security, public safety, traffic & parking management and access control applications. The technology and services provided by the Company help clients move people, assets and data safely and securely through airports, warehouses, schools, national borders, and many other applications and environments. OMNIQ’s customers include government agencies and leading Fortune 500 companies from several sectors, including manufacturing, retail, distribution, food and beverage, transportation and logistics, healthcare, and oil, gas, and chemicals. Since 2014, annual revenues have grown to more than $50 million from clients in the USA and abroad. The Company currently addresses several billion-dollar markets, including the Global Safe City market, forecast to grow to $29 billion by 2022, and the Ticketless Safe Parking market, forecast to grow to $5.2 billion by 2023.

Information about Forward-Looking Statements
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. This release contains “forward-looking statements” that include information relating to future events and future financial and operating performance. The words “anticipate”, “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for the Company’s products particularly during the current health crisis , the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, the Company’s ability to manage credit and debt structures from vendors, debt holders and secured lenders, the Company’s ability to successfully integrate its acquisitions, and other information that may be detailed from time-to-time in OMNIQ Corp.’s filings with the United States Securities and Exchange Commission. Examples of such forward looking statements in this release include, among others, statements regarding revenue growth, driving sales, operational and financial initiatives, cost reduction and profitability, and simplification of operations. For a more detailed description of the risk factors and uncertainties affecting OMNIQ Corp., please refer to the Company’s recent Securities and Exchange Commission filings, which are available at http://www.sec.gov. OMNIQ Corp. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law.

Investor Contact:
888-309-9994
ir@omniq.com

Continue Reading

Trending

Roboticulized is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Roboticulized digests / hand picks the latest news about the AI industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Roboticulized.com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania